Tags

Type your tag names separated by a space and hit enter

Percutaneous pulmonary Melody® valve implantation in small conduits.
Arch Cardiovasc Dis. 2017 Oct; 110(10):517-524.AC

Abstract

BACKGROUND

The Melody® pulmonary valve has received approval for the treatment of dysfunctional right ventricular (RV) outflow tract conduits ≥16mm.

AIMS

To investigate technical and clinical outcomes in patients who underwent percutaneous pulmonary valve implantation (PPVI) in conduits ≤16mm.

METHODS

Eleven patients were enrolled retrospectively between 2000 and 2015 in a cardiac referral centre.

RESULTS

The PPVI indications were obstruction (n=5); regurgitation (n=1); and mixed lesions (n=5). Pre-stenting was performed during the procedure in seven cases. Three of the remaining four patients had previous stent implantation. The mean maximal dilatation balloon diameter/surgical initial diameter ratio was 1.3. Procedural haemodynamics showed a decrease in peak RV to pulmonary artery gradient (mmHg) from 50 (14-86) to 11 (5-23) (P<0.001), in RV systolic pressure (mmHg) from 69 (35-110) to 40 (25-50) (P=0.006) and in RV/aortic systolic pressure ratio from 0.8 (0.4-1.0) to 0.4 (0.3-0.6) (P=0.004). Acute device-related complications occurred in four patients (36.4%): two confined conduit tears managed with placement of a covered stent; and two vascular access complications. Mean follow-up after PPVI was 3.9 years (41 days to 6.7 years). At last follow-up, one patient had undergone surgical conduit replacement for recurrent conduit stenosis, one had percutaneous pulmonary valve dilatation and two had developed bacterial endocarditis and undergone surgical conduit replacement. Freedom from valve dysfunction at 1, 2 and 3 years was 91%, 91% and 82%, respectively.

CONCLUSIONS

PPVI is feasible in small conduits ≤ 16mm with good procedural and early haemodynamic results, postponing the need for surgery. These results are not sustainable over time. Larger studies are needed to determine if bare-metal stent implantation as a bridge to surgical replacement provides the same results in this specific population.

Authors+Show Affiliations

Centre de reference malformations cardiaques congenitales complexe - M3C, hôpital Necker-Enfants-Malades, hôpital européen Georges-Pompidou, AP-HP, 149, rue de Sèvres, 75015 Paris cedex, France; Université Paris-Descartes, Paris, France. Electronic address: myriam.bensemlali@gmail.com.Centre de reference malformations cardiaques congenitales complexe - M3C, hôpital Necker-Enfants-Malades, hôpital européen Georges-Pompidou, AP-HP, 149, rue de Sèvres, 75015 Paris cedex, France.Centre de reference malformations cardiaques congenitales complexe - M3C, hôpital Necker-Enfants-Malades, hôpital européen Georges-Pompidou, AP-HP, 149, rue de Sèvres, 75015 Paris cedex, France; Université Paris-Descartes, Paris, France.Centre de reference malformations cardiaques congenitales complexe - M3C, hôpital Necker-Enfants-Malades, hôpital européen Georges-Pompidou, AP-HP, 149, rue de Sèvres, 75015 Paris cedex, France; Université Paris-Descartes, Paris, France.Centre de reference malformations cardiaques congenitales complexe - M3C, hôpital Necker-Enfants-Malades, hôpital européen Georges-Pompidou, AP-HP, 149, rue de Sèvres, 75015 Paris cedex, France; Université Paris-Descartes, Paris, France.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28549918

Citation

Bensemlali, Myriam, et al. "Percutaneous Pulmonary Melody® Valve Implantation in Small Conduits." Archives of Cardiovascular Diseases, vol. 110, no. 10, 2017, pp. 517-524.
Bensemlali M, Malekzadeh-Milani S, Mostefa-Kara M, et al. Percutaneous pulmonary Melody® valve implantation in small conduits. Arch Cardiovasc Dis. 2017;110(10):517-524.
Bensemlali, M., Malekzadeh-Milani, S., Mostefa-Kara, M., Bonnet, D., & Boudjemline, Y. (2017). Percutaneous pulmonary Melody® valve implantation in small conduits. Archives of Cardiovascular Diseases, 110(10), 517-524. https://doi.org/10.1016/j.acvd.2016.12.013
Bensemlali M, et al. Percutaneous Pulmonary Melody® Valve Implantation in Small Conduits. Arch Cardiovasc Dis. 2017;110(10):517-524. PubMed PMID: 28549918.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Percutaneous pulmonary Melody® valve implantation in small conduits. AU - Bensemlali,Myriam, AU - Malekzadeh-Milani,Sophie, AU - Mostefa-Kara,Meriem, AU - Bonnet,Damien, AU - Boudjemline,Younes, Y1 - 2017/05/23/ PY - 2016/06/11/received PY - 2016/09/03/revised PY - 2016/12/15/accepted PY - 2017/5/28/pubmed PY - 2018/10/4/medline PY - 2017/5/28/entrez KW - Cardiopathies congénitales KW - Congenital heart diseases KW - Melody(®) valve KW - Paediatrics KW - Percutaneous valve implantation KW - Pédiatrie KW - Remplacement valvulaire percutané KW - Valve Melody(®) SP - 517 EP - 524 JF - Archives of cardiovascular diseases JO - Arch Cardiovasc Dis VL - 110 IS - 10 N2 - BACKGROUND: The Melody® pulmonary valve has received approval for the treatment of dysfunctional right ventricular (RV) outflow tract conduits ≥16mm. AIMS: To investigate technical and clinical outcomes in patients who underwent percutaneous pulmonary valve implantation (PPVI) in conduits ≤16mm. METHODS: Eleven patients were enrolled retrospectively between 2000 and 2015 in a cardiac referral centre. RESULTS: The PPVI indications were obstruction (n=5); regurgitation (n=1); and mixed lesions (n=5). Pre-stenting was performed during the procedure in seven cases. Three of the remaining four patients had previous stent implantation. The mean maximal dilatation balloon diameter/surgical initial diameter ratio was 1.3. Procedural haemodynamics showed a decrease in peak RV to pulmonary artery gradient (mmHg) from 50 (14-86) to 11 (5-23) (P<0.001), in RV systolic pressure (mmHg) from 69 (35-110) to 40 (25-50) (P=0.006) and in RV/aortic systolic pressure ratio from 0.8 (0.4-1.0) to 0.4 (0.3-0.6) (P=0.004). Acute device-related complications occurred in four patients (36.4%): two confined conduit tears managed with placement of a covered stent; and two vascular access complications. Mean follow-up after PPVI was 3.9 years (41 days to 6.7 years). At last follow-up, one patient had undergone surgical conduit replacement for recurrent conduit stenosis, one had percutaneous pulmonary valve dilatation and two had developed bacterial endocarditis and undergone surgical conduit replacement. Freedom from valve dysfunction at 1, 2 and 3 years was 91%, 91% and 82%, respectively. CONCLUSIONS: PPVI is feasible in small conduits ≤ 16mm with good procedural and early haemodynamic results, postponing the need for surgery. These results are not sustainable over time. Larger studies are needed to determine if bare-metal stent implantation as a bridge to surgical replacement provides the same results in this specific population. SN - 1875-2128 UR - https://www.unboundmedicine.com/medline/citation/28549918/Percutaneous_pulmonary_Melody®_valve_implantation_in_small_conduits_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1875-2136(17)30095-5 DB - PRIME DP - Unbound Medicine ER -